Gynecologic Cancers
Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer
August 08, 2022
Video
Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor.
Nurses Play Key Role in Facilitating Maintenance Therapy With PARP Inhibitors in Ovarian Cancer
August 02, 2022
Article
Paula Anastasia, RN, MN, AOCN, discusses the value of germline testing and the role of maintenance PARP inhibitor therapy in optimized ovarian cancer treatment.
Oncology Nursing News Top Stories: July 2022
July 29, 2022
Article
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from July 2022.
PARP Inhibitor Niraparib Shows Efficacy as Maintenance Treatment in Advanced Ovarian Cancer
July 29, 2022
Article
Chinese patients with newly diagnosed advanced ovarian cancer whose disease responsed to first-line chemotherapy experienced significantly improved progression-free survival with niraparib.
ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical Implementation
July 27, 2022
Article
In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.
Uniform Baseline Measurements Are Crucial in Improving Standard of Supportive Care
July 26, 2022
Article
Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.
Mirvetuximab Soravtansine Is Under Priority Review for FRα-High, Platinum-Resistant Ovarian Cancer
July 18, 2022
Article
Mirvetuximab soravtansine (IMGN853) has been granted priority review by the FDA for the treatment of patients with FRα-high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.
Bevacizumab With Olaparib Extends Time to Toxicity in Patients With Newly Diagnosed Ovarian Cancer
July 14, 2022
Article
Patients receiving bevacizumab plus olaparib to treat newly diagnosed ovarian cancer experienced significantly longer time without signs of toxicity compared with placebo.
Are Oncology Nurses Underutilized in Positively Affecting the Opioid Epidemic?
July 07, 2022
Article
Gretchen McNally PhD, ANP-BC, AOCNP, discusses the potential impact advanced practice providers and nurses could have in the opioid pandemic if the correct educational opportunities were available.
Burbage Provides Nursing Perspective on 2022 ASCO Meeting
July 01, 2022
Article
Darcy Burbage, DNP, RN, AOCN, CBCN, discusses the top takeaways from the 2022 ASCO Annual Meeting for oncology nurses.